Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 3/20 | 0.35 |
| ▸ | NOS2 | P35228 | 3/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23139644 | 0.90 | NCF1 (0.42) | CYP2D6NCF1CYP1A2SIGMAR1NOS1 | |
| Decarboxylated Derivative SCHEMBL22472078 | 0.89 | CYP2D6 (0.48) | CYP2D6NCF1CYP1A2SIGMAR1NOS1 | |
| SCHEMBL12820123 | 0.86 | NCF1 (0.48) | CYP2D6NCF1NOS1NOS2NOS3 | |
| Methylamine SCHEMBL27371156 | 0.86 | CYP1A2 (0.48) | CYP1A2SIGMAR1NOS1NOS2NOS3 | |
| SCHEMBL12441541 | 0.86 | NCF1 (0.48) | CYP2D6NCF1NOS1NOS2NOS3 | |
| SCHEMBL178372 | 0.86 | NCF1 (0.48) | CYP2D6NCF1NOS1NOS2NOS3 | |
| SCHEMBL13893972 | 0.86 | CYP2D6 (0.54) | CYP2D6NCF1CYP1A2SIGMAR1NOS1 | |
| SCHEMBL3536114 | 0.86 | CYP2D6 (0.54) | CYP2D6NCF1CYP1A2SIGMAR1NOS1 | |
| SCHEMBL22078896 | 0.86 | CYP2D6 (0.54) | CYP2D6NCF1CYP1A2SIGMAR1NOS1 | |
| SCHEMBL19099823 | 0.86 | CYP2D6 (0.54) | CYP2D6NCF1CYP1A2SIGMAR1NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053953-A1 | A COMPOUND, A REACTION PRODUCT OF SAID COMPOUND AND PRODUCTION METHODS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053953-A1 | A COMPOUND, A REACTION PRODUCT OF SAID COMPOUND AND PRODUCTION METHODS THEREOF | COASY, SQLE, CYP2C9 | CYP2D6 19/4885NCF1 2080/4885CYP1A2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.